Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies

Journal of Immunological Methods

Volumn 231, Issue 1-2, 1999, Pages 11-23

  Green, Larry L ^a  

^a Abgenix   (United States)

Author keywords

Autoimmunity; Cancer; Human monoclonal antibodies; Immunoglobulin genes; Therapeutic antibodies; Transgenic mice; Yeast artificial chromosomes

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN KAPPA CHAIN; MONOCLONAL ANTIBODY;

ANTIBODY AFFINITY; ANTIBODY PRODUCTION; ANTIGEN SPECIFICITY; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC ENGINEERING; HYBRIDOMA; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; YEAST ARTIFICIAL CHROMOSOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; B-LYMPHOCYTES; GENETIC ENGINEERING; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOGLOBULIN VARIABLE REGION; MICE; PROTEIN ENGINEERING;

ANIMALIA; MURINAE; MUS MUSCULUS;

EID: 0033511863     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(99)00137-4     Document Type: Article

References (50)

1. Abramowicz, D., Crusiaux, A., Goldman, M., 1992. Anaphylactic shock after retreatment with OKT3 monoclonal antibody. N. Engl. J. Med. 327, 736.
2. Adair, J.R., 1992. Engineering antibodies for therapy. In: Immunological Reviews. Munksgarrd, Copenhagen, p. 5.
3. Barjorin, D.F., Chapman, P.B., Wong, G.Y., Cody, B.V., Cordon-Cardo, C., Dantes, L., Templeton, M.A., Scheinberg, D., Oettgen, H.F., Houghton, A.N., 1992. Treatment with high dose mouse monoclonal (anti-GD3) antibody R24 in patients with metastatic melanoma. Melanoma Res. 2, 355.
4. Brezinschek, H.P., Brezinschek, R.I., Lipsky, P.E., 1995. Analysis of the heavy chain repertoire of human peripheral B cells using single-cell polymerase chain reaction. J. Immunol. 155, 190.
5. Burke, D.T., Olson, M.V., 1991. Preparation of clone libraries in yeast artificial chromosome vectors. Methods Enzymol. 194, 251.
6. Burrows, P.D., Schroeder, H.W., Jr., Cooper, M.D., 1995. B cell differentiation in humans. In: Honjo, T., Alt, F.W. (Eds.), Immunoglobulin Genes. Academic Press, London, p. 3.
7. Burton, D.R., Barbas, C.F., 1993. Human antibodies from combinatorial libraries. In: Nottingham, C.M. (Ed.), Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Application in Man. Academic Titles, p. 65.
8. Choy, E.H., 1998. Clinical pharmacology and therapeutic potential of monoclonal antibody treatment in rheumatoid arthritis. Drugs Aging 12, 139.
9. Coller, B.S., Anderson, K., Weisman, H.F., 1995. New antiplatelet agents: platelet GPIIb/IIIa antagonists. Thromb. Haemostasis 74, 302.
10. Cox, J.P.L., Tomlinson, I.M., Winter, G., 1994. A directory of human germ-line VK segments reveals a strong bias in their usage. Eur. J. Immunol. 24, 827.
11. de Wildt, R.M.T., Hoet, R.M.A., van Venrooij, W.J., Tomlinson, I.M., Winter, G., 1999. Analysis of heavy and light chain pairings indicates that receptor editing shapes the human antibody repertoire. J. Mol. Biol. 285, 895.
12. Elliott, M.J., Maini, R.N., Feldmann, M., Long-Fox, A., Charles, P., Bij, H., Woody, J.N., 1994. Repeated therapy with monoclonal antibody to tumor necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 344, 1125.
13. Fishwild, D.M., O'Donnell, S.L., Bengoechea, T., Hudson, D.V., Harding, F., Bernhard, S.L., Jones, D., Kay, R.M., Higgins, K.M., Schramm, S.R., Lonberg, N., 1996. High-avidity human Ig K monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat. Biotechnol. 14, 845.
14. Goldenberg, M.M., 1999. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin. Ther. 21, 309.
15. Green, L.L., Jakobovits, A., 1998. Regulation of B cell development by variable gene complexity in mice reconstituted with human immunoglobulin yeast artificial chromosomes. J. Exp. Med. 188, 483.
16. Green, L.L., Hardy, M.C., Maynard-Currie, C.E., Tsuda, H., Louie, D.M., Mendez, M.J., Abderrahim, H., Noguchi, M., Smith, D.H., Zeng, Y., David, N.E., Sasi, H., Garza, D., Brenner, D.G., Hales, J.F., McGuinness, R.P., Capon, D.J., Klapholz, S., Jakobovitz, A., 1994. Antigen-specific human monoclonal antibodies from nice engineered with human Ig heavy and light chain YACs. Nat. Genet. 7, 13.
17. Griffiths, A.D., Hoogenboom, H.R., 1993. Building an in vitro immune system: human antibodies from phage display libraries. In: Nottingham, C.M. (Ed.), Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Application in Man. Academic Titles, p. 45.
18. Jaffers, G.J., Fuller, T.C., Cosimi, A.B., Russell, P.S., Winn, HJ., Colvin, R.B., 1986. Monoclonal antibody therapy. Anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression. Transplantation 41, 572.
19. Jakobovits, A.J., Vergara, G.J., Kennedy, J.L., Hales, J.F., McGuinness, R.P., Casentini-Borocz, D.E., Brenner, D.G., Otten, G.R., 1993a. Analysis of homozygous mutant chimeric mice: Deletion of the immunoglobulin heavy-chain joining region blocks B cell development and antibody production. Proc. Natl. Acad. Sci. U.S.A. 90, 2551.
20. Jakobovits, A., Moore, A.L., Green, L.L., Vergara, G.J., Maynard-Currie, C.E., Austin, H.A., Klapholz, S., 1993b. Germline transmission and expression of a human-derived yeast artificial chromosome. Nature 362, 255.
21. Kahan, B.D., Rajagopalan, P.R., Hall, M., 1999. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin2-receptor monoclonal antibody. Transplantation 67, 276.
22. Kohler, G., Milstein, S., 1975. Continuous culture of fused cells secreting antibody of redefined specificity. Nature 256, 495.
23. Leget, G.A., Czuczman, M.S., 1998. Use of rituximab, the new FDA-approved antibody. Curr. Opin. Oncol. 10, 548.
24. Lonberg, N., Taylor, L.D., Harding, F.A., Trounstine, M., Higgins, K.M., Schramm, S.R., Kuo, C.-C., Mashayekh, R., Wymore, K., McCabe, J.G., Munoz-Regan, D., O'Donnell, S.L., Lapachet, E.S.G., Bengoechea, T., Kay, R.M., Fishwild, D.M., Carmack, C.E., Huszar, D., 1994. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 368, 856.
25. Matsuda, F., Honjo, T., 1993. Organization of the human immunoglobulin heavy chain locus. Adv. Immunol. 62, 1.
26. Melero, I., Sheford, W.W., Newby, S.A., Aruffo, A., Ledbetter, J.A., Hellstrom, K.E., Mittler, R.S., Chen, L., 1997. Monoclonal antibodies against the 4-1BB T cell activation molecule established tumors. Nat. Med. 3, 682.
27. Mendez, M.J., Green, L.L., Corvalan, J.R.F., Jia, X.-C., Maynard-Currie, C.E., Yang, X.-d., Gallo, M.L., Louie, D.M., Lee, D.V., Erickson, K.L., Luna, J., Roy, C.M.-N., Abderrahim, H., Kirschenbaum, F., Noguchi, M., Smith, D.H., Fukushima, A., Hales, J.F., Finer, M.H., Davis, C.G., Zsebo, K.M., Jakobovits, A., 1997. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat. Genet. 15, 146.
28. Meredith, R.F., LoBuglio, A.F., Spencer, E.B., 1997. Recent progress in radioimmunotherapy for cancer. Oncology (Huntington) 11, 979.
29. Morrison, S.L., Oi, V.T., 1989. Chimeric immunoglobulin genes. In: Honjo, T., Alt, F.W., Rabbits, T.H. (Eds.), Immunoglobulin Genes. Academic Press, London, p. 260.
30. Nashan, B., Light, S., Hardie, I.R., Lin, A., Johnson, J.R., 1999. Reduction of acute renal allograft rejection by daclizumab. Transplantation 67, 110.
31. Present, D.H., Rutgeerts, P., Targan, S., Hanauer, S.B., Mayer, L., van Hogezand, R.A., Podolsky, D.K., Sands, B.E., Braakman, T., DeWoody, K.L., Schaible, T.F., van Deventer, S.J., 1999. Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Eng. J. Med. 6, 1398.
32. Reiter, Y., Pastan, I., 1998. Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis. Trends Biotechnol. 16, 513.
33. Riechmann, L., Clark, M., Waldmann, H., Winter, G., 1988. Reshaping human antibodies for therapy. Nature 332, 323.
34. Sanz, I., Shou-Shu, W., Meneses, G., Fischbach, M., 1994. Molecular characterization of human Ig heavy chain DIR genes. J. Immunol. 152, 3958.
35. Scallon, B.J., Moore, M.A., Trinh, H., Knight, D.M., Ghrayeb, J., 1995. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 7, 251.
36. Schable, K.F., Zachau, H.-G., 1993. The variable genes of the human immunoglobulin K locus. Biol. Chem. Hoppe-Seyler 374, 1001.
37. Schneider, H., Chaovapong, W., Matthews, D.J., Karkaria, C., Cass, R.T., Zhan, H., Boyle, M., Lorenzini, T., Elliot, S.G., Giebel, L.B., 1997. Homodimerization of erythropoietin receptor by a bivalent monoclonal antibody triggers cell proliferation and differentiation of erythroid precursors. Blood 89, 473.
38. Smith, S.L., 1996. Ten years of orthoclone OKT3 (muromonabCD3): a review. J. Transp. Coord. 6, 109.
39. Storch, G.A., 1998. Humanized monoclonal antibody for prevention of respiratory syncytial virus infection. Pediatrics 102, 648.
40. Taylor, L.D., Carmack, C.E., Huszar, D., Higgins, K.M., Mashayekh, R., Sequar, G., Schramm, S.R., Kuo, C.-C., O'Donnell, S.L., Kay, R.M., Woodhouse, C.S., Lonberg, N., 1994. Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM. Int. Immunol. 6, 579.
41. Tsuda, H., Maynard-Currie, C.E., Reid, L.H., Yoshida, T., Edamura, K., Maeda, N., Smithies, O., Jakobovits, A., 1997. Inactivation of the mouse HPRT locus by a 203-bp retroposon insertion and a 55-kb gene-targeted deletion: establishment of new HPRT-deficient mouse embryonic stem cell lines. Genomics 42, 413.
42. Tuaillon, N., Taylor, L.D., Lonberg, N., Tucker, P.W., Capra, J.D., 1993. Human immunoglobulin heavy-chain minilocus recombination in transgenic mice: gene segment use in μ, and γ transcripts. Proc. Natl. Acad. Sci. U.S.A. 90, 6287.
43. Yamada, M., Wasserman, R., Reichard, B.A., Shane, S., Caton, A.J., Rovera, G., 1991. Preferential utilization of specific immunoglobulin heavy chain diversity and joining segments in adult human peripheral B lymphocytes. J. Exp. Med. 173, 395.
44. Vaughan, T.J., Osbourn, J.K., Tempest, P.R., 1998. Human antibodies by design. Nat. Biotechnol. 16, 535.
45. Waldmann, T.A., O'Shea, J., 1998. The use of antibodies against the IL-2 receptor in transplantation. Curr. Opin. Immunol. 10, 507.
46. Weinstein, J.N., Eger, R.R., Covell, D.G., Black, C.D., Mulshine, J., Carrasquillo, J.A., Larson, S.M., Keenan, A.M., 1987. The pharmacology of monoclonal antibodies. Ann. N. Y. Acad. Sci. 507, 199.
47. Winter, G., Milstein, C., 1991. Man-made antibodies. Nature 349, 495.
48. Yang, X.-d., Jia, X.C., Corvalan, J.R., Wang, P., Davis, C.G., Jakobovits, A., 1999a. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 59, 1236.
49. Yang, X.-d., Corvalan, J.R.F., Wang, P., Roy, C.M.-N., Davis, C.G., 1999b. Fully human anti-interleukin-8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states. J. Leukocyte Biol. 66, 401.
50. Zuckier, L.S., Rodriguez, L.D., Scharff, M.D., 1989. Immunologic and pharmacologie concepts of monoclonal antibodies. Semin. Nucl. Med. 19, 166.